Inovio Pharmaceuticals, Inc. (INO) Covered Calls

Inovio Pharmaceuticals, Inc. is a biotechnology company focused on the development and commercialization of DNA medicines to treat HPV-related diseases, cancer, and infectious diseases. The firm utilizes its proprietary CELLECTRA smart device technology to deliver optimized DNA plasmids directly into cells, triggering a functional immune response. Its lead program, INO-3107, is currently under FDA review as a potential breakthrough treatment for Recurrent Respiratory Papillomatosis (RRP).

You can sell covered calls on Inovio Pharmaceuticals, Inc. to lower risk and earn monthly income. Born To Sell's covered call screener gives you customized search capabilities across all possible covered calls but here are a couple of examples for INO (prices last updated Wed 1:50 PM ET):

Want to make money with covered calls?  Sign Up For A Free Trial

Core Business and Products

Inovio Pharmaceuticals, Inc. (NASDAQ: INO) is at the forefront of the DNA medicine revolution, utilizing a specialized platform that combines computer-aided design of DNA plasmids with a unique delivery mechanism. Unlike traditional vaccines or mRNA therapies, Inovio’s DNA medicines are designed to teach the body’s own cells to produce specific proteins that stimulate a robust T-cell and antibody response. This process is facilitated by the CELLECTRA delivery device, which uses brief electric pulses to increase cell membrane permeability, ensuring the DNA reaches the cell nucleus.

The company’s lead candidate, INO-3107, is a DNA immunotherapy targeting RRP, a rare disease caused by HPV types 6 and 11. In late 2025, the FDA accepted the company’s Biologics License Application (BLA) for review, setting a PDUFA target action date of October 30, 2026. This represents a historic milestone as the company’s first potential commercial product. Additionally, the firm is advancing INO-5412 in collaboration with Akeso for the treatment of glioblastoma (GBM) and maintaining a pipeline of candidates for various HPV-associated cancers and infectious diseases.

Competitive Landscape

The genetic medicine landscape is dominated by mRNA giants and traditional vaccine manufacturers, but Inovio competes by offering a platform that does not require chemical adjuvants or lipid nanoparticles (LNPs), potentially reducing side effects and storage complexity. However, the company faces significant pressure to prove its commercial viability after years of development. In April 2026, the firm completed a $17.5 million public offering to extend its cash runway through its critical PDUFA date. The competitive advantage hinges on the durability of the immune response generated by its DNA plasmids compared to other modalities.

Publicly traded competitors that are optionable include:

1. Moderna, Inc.: The leader in mRNA technology that competes for market share in the next-generation infectious disease and oncology vaccine sectors.
2. BioNTech SE: A major competitor in the immunotherapy space, utilizing mRNA and other platforms to target cancer and viral diseases.
3. Vertex Pharmaceuticals Incorporated: A powerhouse in genetic medicines that represents the broader competition for innovative therapies in rare disease categories.
4. Novavax, Inc.: A vaccine developer that, while focused on protein-based technology, competes for institutional capital in the high-volatility biotech sector.

Strategic Outlook and Innovation

The strategic roadmap for 2026 is almost entirely centered on the October 30 PDUFA date for INO-3107. Success in this review would transition Inovio from a research-stage organization to a commercial-stage pharmaceutical company. Management is currently building out its commercial infrastructure, including a specialized "patient HUB" and logistics partnerships, to ensure a rapid launch upon approval. In parallel, the company is focusing on "capital-light" innovation through clinical collaborations, such as its partnership with Akeso to combine DNA immunotherapy with dual checkpoint inhibition for brain cancer.

Innovation at the firm is evolving with its next-generation DNA-encoded monoclonal antibodies (DMAbs) and DNA-encoded proteins (DPROTs). These technologies aim to turn the human body into a "bio-factory" for antibodies, potentially eliminating the need for expensive and complex lab-grown protein manufacturing. By integrating these advancements with its CELLECTRA delivery devices, Inovio aims to create a versatile therapeutic platform that can address everything from chronic infections to rare genetic disorders, providing a more stable and cost-effective alternative to current biologics.

Want more examples? INN Covered Calls | INOD Covered Calls